Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - NETs and endocrine tumours

1223 - Potential Therapeutic Targets in Recurrent and Metastatic Parathyroid Carcinomas revealed by next-generation sequencing.


22 Oct 2018


Poster Discussion session - NETs and endocrine tumours


Translational Research

Tumour Site

Endocrine Tumours


Ming Cui


Annals of Oncology (2018) 29 (suppl_8): viii149-viii149. 10.1093/annonc/mdy280


M. Cui1, Y. Hu2, Q. Liao1, Y. Zhao1

Author affiliations

  • 1 Department Of General Surgery, PUMCH, 100730 - Beijing/CN
  • 2 Department Of General Surgery, PUMCH, Beijing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1223


Parathyroid carcinoma (PC) is a rare endocrine malignancy. Complete surgical resection is the most effective method for the management of PC, however, more than half of PC patients would have recurrent or metastatic lesions. In inoperable disease, treatment options are still limited since chemotherapy and radiotherapy have been generally ineffective in the treatment of PC. Emerging evidence from clinical practice indicated that pre-therapeutic test of molecular biomarkers in tumors may predict the efficacy of the respective targeted drugs. Therefore, understanding the genetic landscape of PC can help in determining whether targeted therapy has potential to be a novel option to treat this refractory disease.


DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections from 19 recurrent or metastatic PC samples. A panel of 560 genes was sequenced with next-generation sequencing (NGS) using Illumina HiSeq X platform to identify genomic alterations at an average sequencing depth of 581×.


A total of 190 genomic alterations were identified. Nine PC samples (47%) harbored at least one potentially actionable genomic alteration including: ROS1 (5/19; 26%), PTEN (3/19; 16%), TSC1 (2/19; 11%), PIK3CA (1/19; 5%), AKT1 (1/19; 5%), MTOR (1/19; 5%), ERBB2 (1/19; 5%), NTRK1 (1/19; 5%), IDH1 (1/19; 5%), and FGFR3 (1/19; 5%). CDC73 mutations were detected in 9/19 (47%) PC samples. Additional recurrent genomic alterations were identified in MSH2 (15/19; 79%), AR (9/19; 47%), BCR (8/19; 42%), SLC45A3 (6/19; 32%), MAGI1 (5/19; 26%), ZNF521 (4/19; 21%), KMT2C (4/19; 21%), and NOTCH4 (4/19; 21%).


The present study identified a considerable frequency of potentially actionable genomic alterations in PC patients for the first time. A series of recurrent mutant genes have been detected as well. The present study would contribute to both selection of novel targeted therapies for PC and further molecular understanding of this refractory malignancy.

Clinical trial identification

Legal entity responsible for the study

Yupei Zhao.


This work was supported by the Peking Union Medical College Innovative Team Development Program (2016) and the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS-I2M) (2017-I2M-1-001).

Editorial Acknowledgement



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.